XPO Form 4: Director Landry disposes of 3,250 XPO shares

Rhea-AI Filing Summary

XPO, Inc. (XPO) director Allison Landry reported a sale of 3,250 shares of company common stock on 09/11/2025 at a reported price of $135.0369 per share. After the transaction she beneficially owns 5,875 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/12/2025. No options or derivative transactions were reported.

Positive

• None.

Negative

• Director sale disclosed: Allison Landry disposed of 3,250 shares, reducing direct beneficial ownership to 5,875 shares.

Insights

Financial Analyst

TL;DR: A director sold a portion of holdings; transaction appears routine and provides limited new information.

The Form 4 shows a single open-market disposition of 3,250 common shares at $135.0369, leaving 5,875 shares beneficially owned. There are no derivative transactions or plan-based trades disclosed. For investors, this is a clear disclosure of insider liquidity but not, by itself, evidence of company-level changes in operations or financial condition.

Corporate Governance Expert

TL;DR: Director-level sale was properly reported; filing contains standard disclosure and a dated signature by attorney-in-fact.

The filing identifies the reporting person as a director and indicates a direct ownership form. The report includes the required signature by an attorney-in-fact dated 09/12/2025. There are no amendments, derivative holdings, or plan confirmations noted on the form, suggesting standard compliance with Section 16 reporting obligations.

Insider Trade Summary

Net Seller: 3,250 shares

Net Sell 1 txn

Insider Landry Allison

Role Director

Sold 3,250 shs ($439K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,250	$135.0369	$439K

Holdings After Transaction: Common Stock — 5,875 shares (Direct)

FAQ

What did XPO director Allison Landry report on Form 4?

She reported the sale of 3,250 common shares on 09/11/2025 at a price of $135.0369, leaving 5,875 shares beneficially owned.

When was the Form 4 for XPO filed and who signed it?

The filing was signed on 09/12/2025 by Wendy Cassity as attorney-in-fact.

Were any derivative securities reported in this XPO Form 4?

No derivatives were reported. Table II shows no entries for options, warrants, or convertible securities.

What is the reporting person's relationship to XPO?

Allison Landry is identified as a director of XPO, Inc.

Does the Form 4 indicate a Rule 10b5-1 trading plan or amendment?

No indication of a 10b5-1 plan or any amendment date appears in the provided content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 09/12/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landry Allison

(Last) (First) (Middle)

C/O XPO, INC.

FIVE AMERICAN LANE

(Street)

GREENWICH CT 06831

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
XPO, Inc. [ XPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		S		3,250	D	$135.0369	5,875	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Wendy Cassity, Attorney-in-Fact	09/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.